CALL FOR ABSTRACTS

AMERICAN SOCIETY OF GENE & CELL THERAPY

23RD ANNUAL MEETING

MAY 12-15, 2020
HYNES CONVENTION CENTER

ANNUALMEETING.ASGCT.ORG
#ASGCT20
SUBMIT YOUR ABSTRACT TO ASGCT AND PRESENT YOUR RESEARCH!

The ASGCT 23rd Annual Meeting is the primary forum for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by advancing gene and cell therapies to alleviate human disease.

Why should you submit an abstract to ASGCT?

• Great opportunity to present and discuss your research with your peers and leaders in the gene and cell therapy field.
• Free registration for Associate Members who are the first and presenting author on an abstract.
• Awards and travel grants are given to approximately 150 abstract submitters based on abstract scores. Presentation and publication opportunities for accepted abstracts, with nearly 25 percent of submitted abstracts accepted for oral presentation.
• All accepted abstracts will be published in the online Supplement to the Society’s journal, Molecular Therapy.

Previous Meeting Attendance

Over the past five years attendance to the ASGCT Annual Meeting has risen dramatically, with attendance increasing by 77 percent from 2017 to 2019.
AWARDS AND INCENTIVES

ASGCT is proud to offer free registration to the Annual Meeting for students and postdoctoral fellows who are Associate Members of ASGCT and the first and presenting author of an accepted abstract!

Meritorious Abstract Travel Awards
ASGCT supports the travel of approximately 150 Associate Members each year through the Meritorious Abstract Travel Award program. Awards are given out based on high abstract scores and recipients will receive a certificate and a travel reimbursement stipend of up to $500 for domestic awardees and $600 for international awardees.

Excellence in Research Awards
The top ten to fifteen abstracts submitted by students and fellows will receive an Excellence in Research Award. Recipients will be announced at the end of the George Stamatoyannopoulos plenary lecture on Wednesday, May 13, 2020 and will receive a monetary award of $500 along with a special plaque.

Outstanding Poster Presentation Awards
The top poster presentations from each of the three poster sessions that occur during the ASGCT Annual Meeting are awarded Outstanding Poster Presentation Awards. Awardees are honored through notification to all meeting attendees and receive a special certificate for their contributions.

Underrepresented Minority Travel Awards
ASGCT will offer a limited number of Underrepresented Minority Travel Awards ($500 value) to Associate Members submitting an abstract to the meeting. Eligible candidates must be a U.S. resident and self-identify as African American, Pacific Islander, Hispanic, or Native American.

Poster Funding
Up to 30 Associate Members will receive funding ($129 value) for their poster production. ASGCT will pay the cost for the poster production directly to the poster printing service.
ABSTRACT SUBMISSION INFORMATION

There is no fee to submit an abstract and free registration for the Annual Meeting will be given to Associate Members who are first and presenting author of an abstract. Approximately 25 percent of the abstracts submitted will be eligible for oral presentation based on the review scores. All accepted abstracts will be published in the May supplement to Molecular Therapy.

Eligibility

- ASGCT Members and non-Members are eligible to submit an abstract.
- Submitting an abstract does not register you for the meeting. You must register for the meeting to present your abstract.

Ineligibility

- Papers that have been accepted for publication or published prior to the abstract submission deadline may not be submitted unless special consideration is requested.
- If your abstract was previously accepted for presentation at ASGCT or another national/international meeting, do not submit the abstract unless special permission is requested and granted from ASGCT.

International Abstract Submitters

International abstract submitters who plan to attend the ASGCT 23rd Annual Meeting will need to apply for a VISA. The amount of time required to obtain a VISA has increased tremendously, so please apply early. Abstract submitters can generate invitation letters online at annualmeeting.asgct.org/am20/abstracts. If you need assistance obtaining your letter of invitation, please contact Alex Peterson (apeterson@asgct.org) at the ASGCT Office.

Notification of Abstract Acceptance

Notification regarding acceptance of abstracts will be delivered via email on April 6, 2020. Meritorious Abstract Travel Awards, Excellence in Research Awards, and Underrepresented Minority Travel Awards acceptance and letters will also be sent at this time.

Acceptance of Presentation

All notified abstract presenters are required to accept their presentation as instructed in their notification email. This can be done online through the abstract submission site.

Late Breaking Abstract Submissions

ASGCT will not be accepting Late Breaking Abstract submissions for the 23rd Annual Meeting.

Abstract Questions

For all questions regarding the abstract submission process, please contact Coe-Truman Technologies’ Technical Support by phone at 1-217-398-1792 or by email at support@abstractsonline.com. If you would like to make changes to your abstract after submitting, you will now be able to return directly to your abstract and make changes until the deadline.

Abstract Submissions Open: November 18, 2019
Abstract Submissions Deadline: January 29, 2020 at 11:59 p.m. CST.
To submit your abstract, please go to annualmeeting.asgct.org/am20/abstracts.
When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract.

A1 – RNA Virus Vectors
A2 – AAV Vectors – Virology and Vectorology
A3 – AAV Vectors – Preclinical and Proof-of-Concept Studies
A4 – AAV Vectors – Clinical Studies
B – Gene Targeting and Gene Correction (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category)
C – Oligonucleotide Therapeutics (siRNAs, aptamers, antagonirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
D – Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics (Including exosomes)
E1 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
E2 – Cardiovascular and Pulmonary Diseases
E3 – Neurologic Diseases (Including Ophthalmic and Auditory Diseases)
E4 – Musculo-skeletal Diseases
E5 – Cancer – Immunotherapy, Cancer Vaccines
E6 – Cancer – Oncolytic Viruses
E7 – Cancer – Targeted Gene and Cell Therapy
E8 – Hematologic and Immunologic Diseases
F – Immunological Aspects of Gene Therapy and Vaccines (Includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)
G – Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)
H1 – Vector and Cell Engineering, Production or Manufacturing
H2 – Pharmacology/Toxicology Studies or Assay Development